CYTO — Cytophage Technologies Cashflow Statement
0.000.00%
- CA$10.52m
- CA$11.29m
Annual cashflow statement for Cytophage Technologies, fiscal year end - December 31st, CAD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | ARS |
Standards: | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final |
Net Income/Starting Line | -3.24 | -3.68 | -4.64 | -7.86 |
Depreciation | ||||
Non-Cash Items | 0.054 | 0.45 | 0.832 | 2.69 |
Unusual Items | ||||
Other Non-Cash Items | ||||
Changes in Working Capital | -0.147 | -0.075 | 0.432 | -0.304 |
Change in Accounts Receivable | ||||
Change in Prepaid Expenses | ||||
Change in Payable / Accrued Expenses | ||||
Cash from Operating Activities | -3.03 | -2.94 | -2.86 | -4.77 |
Capital Expenditures | -0.333 | -0.381 | -0.162 | -1.3 |
Purchase of Fixed Assets | ||||
Other Investing Cash Flow Items | — | — | -2.46 | 7.62 |
Other Investing Cash Flow | ||||
Cash from Investing Activities | -0.333 | -0.381 | -2.62 | 6.32 |
Financing Cash Flow Items | -0.091 | 0 | 2.45 | -0.029 |
Other Financing Cash Flow | ||||
Net Issuance / Retirement of Stock | ||||
Net Issuance / Retirement of Debt | ||||
Cash from Financing Activities | 6.58 | 0.728 | 3.26 | -0.06 |
Beginning Cash Balance | ||||
Ending Cash Balance | ||||
Net Change in Cash | 3.22 | -2.6 | -2.21 | 1.49 |